Showing posts with label Product Recall. Show all posts
Showing posts with label Product Recall. Show all posts

Saturday, October 19, 2019

J&J recalls 33,000 bottles of baby powder as FDA finds asbestos in sample


Johnson & Johnson said on Friday it is recalling around 33,000 bottles of baby powder in the United States after US health regulators found trace amounts of asbestos in samples taken from a bottle purchased online.

J&J shares fell more than 6 percent to close at $127.70.

The move marks the first time the company has recalled its iconic baby powder for possible asbestos contamination, and the first time US regulators have announced a finding of asbestos in the product. Asbestos is a known carcinogen that has been linked to deadly mesothelioma.

The recall is the latest blow to the more than 130-year-old US healthcare conglomerate that is facing thousands of lawsuits over a variety of products, including baby powder, opioids, medical devices and the antipsychotic Risperdal.

A jury last week ordered the company to pay $8 billion to a plaintiff in a case claiming J&J downplayed the risks of Risperdal. That award is not expected to stand, the company and legal experts have said.

J&J faces more than 15,000 lawsuits from consumers claiming its talc products, including Johnson's Baby Powder, caused their cancer.

On a conference call with reporters on Friday, Dr. Susan Nicholson, head of Women’s Health in the company's medical safety organization, called the asbestos finding "extremely unusual," adding that it was "inconsistent with our testing to date."

The voluntary recall announced on Friday is limited to one lot of Johnson's Baby Powder produced and shipped in the United States in 2018, the company said. 

J&J in a news release said that testing by the US Food and Drug Administration as recently as a month ago found no asbestos in their talc.

The FDA said in a statement that the latest sampling took place during its testing for asbestos in talc-containing cosmetics that it began reporting this year. A second Johnson’s Baby Powder sample from a different lot tested negative for asbestos, the agency said.

The FDA said it stands by the quality of its testing and results and recommended consumers stop using the product if it comes from the affected lot.

J&J said on the conference call that it received a report from the FDA on Oct. 17 alerting the company about the asbestos finding. It said it has started an investigation and is reviewing manufacturing records and collecting data on the distribution of the lot to determine where the product was shipped.

J&J added that it is working with the FDA to determine the integrity of the tested sample as well as the validity of test results.

THOROUGH INVESTIGATION NEEDED

The type of asbestos discovered by FDA testing has not been found in the mine where the company sources its talc, J&J's Nicholson said. She described it as an environmental contaminant most commonly found in building materials and industrial applications.

J&J said it was too early to confirm whether cross-contamination of the sample had caused a false positive, whether the sample was taken from a bottle with an intact seal or whether it was prepared in a controlled environment. It added that it could not confirm whether the tested product was authentic or counterfeit.

"It is so critical that we perform a thorough investigation of the sample to determine the source of contamination," Nicholson said.

Since 2003, talc in Johnson's Baby Powder sold in the United States has come from China through supplier Imerys Talc America, a unit of Paris-based Imerys SA and a co-defendant in much of the talc litigation. Imerys and J&J said the Chinese talc is safe.

J&J has known for decades that asbestos lurked in its talc, Reuters reported last year. Internal company records, trial testimony and other evidence show that from at least 1971 to the early 2000s, the company’s raw talc and finished powders sometimes tested positive for small amounts of asbestos. Company executives, mine managers, scientists, doctors and lawyers fretted over the problem and how to address it, while failing to disclose it to regulators or the public, Reuters found.

J&J has repeatedly said that its talc products are safe, and that decades of studies have shown them to be asbestos-free and that they do not cause cancer.

The FDA test indicated the presence of no greater than 0.00002 percent of chrysotile asbestos in the tested sample, J&J said.

The World Health Organization and other authorities recognize no safe level of exposure to asbestos. While most people exposed never develop cancer, for some, even small amounts of asbestos are enough to trigger the disease years later.

Thousands of the lawsuits against J&J have been consolidated before a New Jersey federal judge, who is currently weighing company motions to disqualify plaintiffs’ expert witnesses, including the head of an asbestos testing lab who has testified in earlier trials that he found the contaminant in J&J powders.

Leigh O’Dell, one of the lead plaintiff attorneys, on Friday said the recall "vindicates the position we’ve been taking for months.”

Wells Fargo analyst Larry Biegelsen said in a research note that the recall could encourage additional lawsuits and prompt the company to pursue a broader settlement.

Jefferies healthcare strategist Jared Holz said J&J has already lost close to $10 billion in market value due to the talc issue over the past year.

He said further downside to J&J stock is likely to be limited because legal concerns over talc are well known and have already taken a toll on the share price. "This is one single bottle within one lot with barely a trace here," he said.

J&J said in February that it had received subpoenas from the US Justice Department and the Securities and Exchange Commission for documents related to the asbestos contamination allegations. A Bloomberg report, which Reuters has confirmed, said those inquiries include a criminal grand jury investigation into how forthright J&J has been in its statements about the safety of its powders.

While talc products make up less than 1 percent of J&J sales expected by analysts to reach $82 billion in 2019, the New Jersey-based healthcare-products maker considers its Baby Powder to be an essential facet of a carefully tended image as a caring company.

source: news.abs-cbn.com

Sunday, April 2, 2017

Ford recalls F-250 pickups that could roll while in park


Ford Motor Co is recalling about 52,600 F-250 pickup trucks sold in the United States and Canada because the vehicles could roll after the driver moves the automatic transmission lever into park position, the company said on Saturday.

The recall, the third announced by Ford this week, affects 2017 model year F-250 vehicles powered by 6.2-liter gasoline engines and built in its Louisville, Kentucky, truck plant, it said in a statement.

Ford, the second-largest US automaker, also said it was unaware of any injuries or accidents associated with the latest issue.

The company said on Wednesday it was recalling 211,000 vehicles in North America to replace potentially faulty side door latches.

Another recall involves 230,000 vehicles that present a fire risk in the engine compartment. Ford said it had reports of 29 fires related to that issue but no injuries.

The Dearborn, Michigan-based automaker had previously recalled nearly 4 million vehicles for door latch issues in six separate announcements since 2014, including 2.4 million vehicles recalled in late 2016.

(Reporting by Frank McGurty; Editing by G Crosse and Bill Trott)

source: news.abs-cbn.com

Wednesday, October 12, 2016

Samsung offers exchange, full refund for Note 7 in Philippines


MANILA - Samsung Philippines on Wednesday urged Galaxy Note 7 owners in the Philippines to power down their devices and exchange them for a different model or get a full refund.

The South Korean electronics giant has halted production of the flagship smartphone after replacement units that followed a global recall were found to overheat and catch fire like the original models.

If customers opt to get the S7 Edge, Samsung said it would reimburse the price difference with the more expensive Note 7.

Samsung advised customers to transact in the store where they bought their phones.

Note 7 owners can also contact Samsung customer care at +63 (2) 422-2111 or visit their website at http://www.samsung.com/ph/note7exchange.

source: www.abs-cbnnews.com

Tuesday, October 11, 2016

Samsung halts sale and exchange of Note 7


SEOUL - Samsung Electronics on Tuesday called a worldwide halt to the sale and exchange of its Galaxy Note 7 smartphone, citing continued safety concerns, and advised all customers to stop using the device immediately.

The dramatic warning came in a written statement issued a little over a month after the world's largest smartphone maker announced a global recall of 2.5 million Note 7s in 10 markets following complaints that its lithium-ion battery exploded while charging.

The unprecedented recall was a major PR blow for the South Korean conglomerate which prides itself on innovation and quality, and the situation only worsened when reports emerged a week ago of replacement phones also catching fire.

Tuesday's statement was the first formal acknowledgement of continued safety concerns and came a day after Samsung acknowledged it was easing production of the flagship smartphone.

"Because consumers' safety remains our top priority, Samsung will ask all carrier and retail partners globally to stop sales and exchanges of the Galaxy Note 7 while an investigation is taking place," the statement said.

Analysts noted that the move came a little late given that a number of major distributors -- US telecom firm AT&T and German rival T-Mobile -- unilaterally announced a halt to sales and exchanges of the model on Sunday.

Samsung said its investigation of the "recently reported cases" involving the Note 7 was being carried out in cooperation with the relevant regulatory bodies in those markets where the recall was ordered.

In the meantime, the company advised any consumer with an original or replacement Galaxy Note 7 to "power down and stop using the device" immediately.

Analysts have suggested that Samsung, battling ever-fiercer competition in the saturated smartphone market, may have rushed production of the Note 7 with bitter rival Apple's recently released iPhone 7 in mind.

The top-of-the-line Note 7 was crucial to Samsung's growth plans this year, with the company struggling to boost sales, squeezed by Apple in the high-end sector and Chinese rivals in the low-end market, as profit has stagnated.

The trouble with the Note 7 and the handling of the recall, which analysts say could cost up to $2.0 billion, has shone a spotlight on Samsung's management at a time when it is navigating a tricky generational power transfer within its founding Lee family.

Industry experts have criticised the Lee dynasty for controlling the vast group through a complex web of cross-shareholdings, even though they directly own only about five percent of total stocks.

And Samsung is also under pressure from one of its shareholders, the activist US hedge fund Elliott Management run by billionaire Paul Singer.

In a detailed proposal unveiled last week, Elliott laid out a strategy for streamlining Samsung, splitting the company in two, dual-listing the resulting operating company on a US exchange and paying shareholders a special dividend of 30 trillion won ($27 billion).

Elliott argued that Samsung, currently a maze of listed and unlisted companies with a notoriously opaque ownership and management structure, had suffered from a long-term undervaluation in the equity market.

Despite all its problems, Samsung on Friday issued a stronger-than-expected operating profit forecast for the third quarter, thanks largely to strong sales of memory chips and OLED display panels.

source: www.abs-cbnnews.com